• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    $NTLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $BLU alert in real time by email

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors.

    "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through several key value inflection points in the coming years. We look forward to their contributions to our company's success."

    Mr. Forrester has more than 25 years of life sciences experience and has held leadership roles in private and public pharmaceutical companies. He is a co-founder of IDRx, EQRx, Brixton Biosciences and EyeCool Therapeutics and has served as the CEO of Verastem Oncology, COO of Forma Therapeutics, CEO and CFO of CombinatoRx, and CFO of Coley Pharmaceutical. He also serves on the boards of AffyImmune Therapeutics, Pillar Biosciences and Deciduous Therapeutics. Robert also served as Managing Director of the Proprietary Investment Group at MeesPierson and worked as an investment banker at Barclays and UBS. Mr. Forrester holds an LL.B. from Bristol University, UK.

    "I am truly excited to join the OnCusp Board at this transformative moment for the company." Mr. Forrester stated, "I am equally enthusiastic about OnCusp's lead program, CUSP06, a thoughtfully designed second-in-class CDH6 ADC with clearly differentiated attributes. I look forward to working with other board members and the executive team to maximize the potential of the company's promising pipeline."

    Mr. Khuong was most recently General Partner and Senior Advisor at Catalio Capital Management, LP where he served on the Investment Committees of Catalio's flagship private equity strategy and its Credit Opportunities strategy. He previously spent nearly twenty years at OrbiMed Advisors, where he contributed significantly to the firm's growth into one of the premier healthcare-focused investing organizations globally.  At the time of his retirement from OrbiMed in December 2021, Chau was Partner and Member of the Investment Committee for the OrbiMed venture capital funds. He has led or co-led investments into over two dozen life science companies, ultimately resulting in twelve FDA approved medicines or therapeutic devices. Chau has served as a representative on the Board of Directors of numerous public and private biotech companies such as Bellus Health (NASDAQ:BLU), Glaukos (NYSE:GKOS), Inspire Medsystems (NYSE:INSP), Intellia (NASDAQ:NTLA), Rempex (acquired by MDCO), and ReViral Ltd (acquired by Pfizer).  Chau earned a B.S. and an M.P.H., both from Yale University.

    "It is a pleasure to be a part of OnCusp and to collaborate with such an experienced management team," said Mr. Khuong. "I am impressed with the progress that OnCusp has made since its inception last year and look forward to leveraging my financial expertise and extensive relationships to drive growth and success for the company."

    About OnCusp Therapeutics

    OnCusp Therapeutics is a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics. OnCusp was founded by a world-class team with a proven track record in building a startup biotech to the commercialization stage, leading successful global clinical programs, and creating value in mutually beneficial partnerships. OnCusp's business model is to develop preclinical assets to clinical proof of concept and then partner out for commercialization. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp is backed by prominent investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, AIHC Capital, WuXi Biologics HealthCare Venture and 3R Capital. OnCusp has its headquarters in New York City and an office in Shanghai.

    Cision View original content:https://www.prnewswire.com/news-releases/oncusp-therapeutics-announces-appointment-of-robert-forrester-and-chau-khuong-to-board-of-directors-301713160.html

    SOURCE OnCusp

    Get the next $BLU alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLU
    $GKOS
    $INSP
    $NTLA

    CompanyDatePrice TargetRatingAnalyst
    Glaukos Corporation
    $GKOS
    10/1/2025$103.00Buy
    Goldman
    Inspire Medical Systems Inc.
    $INSP
    9/22/2025$89.00Buy → Neutral
    UBS
    Inspire Medical Systems Inc.
    $INSP
    9/2/2025$150.00Outperform
    Evercore ISI
    Inspire Medical Systems Inc.
    $INSP
    8/5/2025$125.00Buy → Hold
    Truist
    Inspire Medical Systems Inc.
    $INSP
    8/5/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    Inspire Medical Systems Inc.
    $INSP
    8/5/2025$110.00Overweight → Neutral
    Analyst
    Glaukos Corporation
    $GKOS
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    Intellia Therapeutics Inc.
    $NTLA
    4/21/2025$21.00Peer Perform → Outperform
    Wolfe Research
    More analyst ratings

    $BLU
    $GKOS
    $INSP
    $NTLA
    SEC Filings

    View All

    Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Intellia Therapeutics, Inc. (0001652130) (Filer)

    9/25/25 4:19:06 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by Glaukos Corporation

    144 - GLAUKOS Corp (0001192448) (Subject)

    9/22/25 4:36:07 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

    8/26/25 5:02:24 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    March 21, 2023 - FDA Roundup: March 21, 2023

    For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

    3/21/23 3:12:46 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glaukos Breaks Ground on New Research, Development, and Manufacturing Facility in Huntsville, Alabama

    Planned Investment of $80+ Million in 200,000 Square-Foot State-of-the-Art Facility Supports Glaukos' Long-Term Growth Plans and Reinforces Commitment to U.S. Manufacturing Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today celebrated the groundbreaking of its new state-of-the-art research, development, and manufacturing facility in Huntsville, Alabama. The new site represents a major milestone in the company's commitment to strengthening U.S. manufacturing, creating high-quality jobs, and driving the next generation of innovation in American

    9/25/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

    One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors with simultaneous publication in the New England Journal of MedicineExpect to complete enrollment in multi-national Phase 3 MAGNITUDE-2 trial in first half 2026 to support a potential BLA filing by 2028 CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE

    9/25/25 9:52:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

    CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-term data from the ongoing Phase 1 trial of investigational nex-z for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) will be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors, taking place September 25-26 in Baveno, Italy. This presentation will include ATTRv-PN disease-relevant measures, including up to three years of patient follow-up. Presentation Details: Title: Efficacy and Safety of Nexi

    9/22/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman initiated coverage on Glaukos with a new price target

    Goldman initiated coverage of Glaukos with a rating of Buy and set a new price target of $103.00

    10/1/25 8:52:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Inspire Medical Systems downgraded by UBS with a new price target

    UBS downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $89.00

    9/22/25 8:12:43 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Evercore ISI initiated coverage on Inspire Medical Systems with a new price target

    Evercore ISI initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $150.00

    9/2/25 8:38:06 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & COO Gilliam Joseph E covered exercise/tax liability with 1,056 shares, decreasing direct ownership by 0.94% to 111,706 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    9/24/25 6:54:01 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    CHIEF DEVELOPMENT OFFICER Navratil Tomas sold $43,541 worth of shares (517 units at $84.22) and covered exercise/tax liability with 483 shares, decreasing direct ownership by 1% to 75,907 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    9/24/25 6:53:20 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    CHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 4,059 shares, decreasing direct ownership by 3% to 150,705 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    9/24/25 6:52:52 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chase William J bought $1,003,000 worth of shares (100,000 units at $10.03), increasing direct ownership by 288% to 134,693 units (SEC Form 4)

    4 - Intellia Therapeutics, Inc. (0001652130) (Issuer)

    8/22/25 4:30:14 PM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

    4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

    1/24/24 4:32:03 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Financials

    Live finance-specific insights

    View All

    Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress

    Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of projections; Tracking to enroll at least 650 patients cumulatively by year-endExpanding total enrollment of the MAGNITUDE study to approximately 1,200 patients, subject to health authority review, with no expected impact on previous projected enrollment or financial runwayExpect to complete enrollment by first half 2026 in the global Phase 3 MAGNITUDE-2 study evaluating nex-z in hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN)Expect to complete randomization in the global Phase 3 HAELO study of lonvoguran ziclumeran (lonvo-z) in heredita

    8/7/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Inspire Medical Systems, Inc. Announces Second Quarter 2025 Financial Results and Updates 2025 Outlook

    MINNEAPOLIS, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2025. Recent Business Highlights Generated revenue of $217.1 million in the second quarter of 2025, an 11% increase over the same quarter last yearAchieved gross margin of 84.0% in the second quarter of 2025Net loss was $3.6 million in the second quarter of 2025. Adjusted net income was $13.3 millionLoss per share was $0.12 in the second quarter of

    8/4/25 4:02:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

    CAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its second quarter 2025 financial results and operational highlights in a conference call on August 7, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call. All participants should ask to be connected to the Intellia Therapeutics conference call.Please visit this link for a simultaneous live webcast of the call. A replay of the call will be available t

    7/31/25 7:30:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Leadership Updates

    Live Leadership Updates

    View All

    Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

    MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

    4/21/25 8:00:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

    Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

    12/5/24 12:12:00 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

    Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patientsConsistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baselinePersistently deep levels of serum TTR

    11/16/24 10:16:00 AM ET
    $NTLA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $BLU
    $GKOS
    $INSP
    $NTLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    11/12/24 10:32:14 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

    SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

    10/4/24 2:09:06 PM ET
    $INSP
    Medical/Dental Instruments
    Health Care